Although there have been no published studies that show an improvement in survival with the addition of SRS for melanoma brain metastases in patients on BRAF plus MEK inhibitors, it may be reasonable to offer upfront SRS if the lesions are larger, to prevent worsening neurological symptoms, with no significant increases in toxicities. Here, MAP2K7 is linked to melanoma.